Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports
Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient surv...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Le, Thuy X. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
renal replacement therapy (RRT) end-stage renal disease (ESRD) light chain deposition disease (LCDD) |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested - 2013, AJKD : official journal of the National Kidney Foundation, Philadelphia, Pa |
|---|---|
| Übergeordnetes Werk: |
volume:69 ; year:2017 ; number:6 ; pages:858-862 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1053/j.ajkd.2016.12.023 |
|---|
| Katalog-ID: |
ELV030399017 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030399017 | ||
| 003 | DE-627 | ||
| 005 | 20230625181531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.ajkd.2016.12.023 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017007000025.pica |
| 035 | |a (DE-627)ELV030399017 | ||
| 035 | |a (ELSEVIER)S0272-6386(17)30511-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DNB |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 530 |q VZ |
| 084 | |a 52.56 |2 bkl | ||
| 100 | 1 | |a Le, Thuy X. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. | ||
| 520 | |a Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. | ||
| 650 | 7 | |a multiple myeloma |2 Elsevier | |
| 650 | 7 | |a kidney failure |2 Elsevier | |
| 650 | 7 | |a case report |2 Elsevier | |
| 650 | 7 | |a renal replacement therapy (RRT) |2 Elsevier | |
| 650 | 7 | |a outcomes |2 Elsevier | |
| 650 | 7 | |a end-stage renal disease (ESRD) |2 Elsevier | |
| 650 | 7 | |a remission |2 Elsevier | |
| 650 | 7 | |a light chain deposition disease (LCDD) |2 Elsevier | |
| 650 | 7 | |a autologous stem cell transplantation (ASCT) |2 Elsevier | |
| 650 | 7 | |a RRT modality |2 Elsevier | |
| 650 | 7 | |a bortezomib |2 Elsevier | |
| 650 | 7 | |a hematologic malignancy |2 Elsevier | |
| 650 | 7 | |a Kidney transplantation |2 Elsevier | |
| 700 | 1 | |a Wolf, Jeffrey L. |4 oth | |
| 700 | 1 | |a Peralta, Carmen A. |4 oth | |
| 700 | 1 | |a Webber, Allison B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Saunders |t The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |d 2013 |d AJKD : official journal of the National Kidney Foundation |g Philadelphia, Pa |w (DE-627)ELV011405082 |
| 773 | 1 | 8 | |g volume:69 |g year:2017 |g number:6 |g pages:858-862 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1053/j.ajkd.2016.12.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 52.56 |j Regenerative Energieformen |j alternative Energieformen |q VZ |
| 951 | |a AR | ||
| 952 | |d 69 |j 2017 |e 6 |h 858-862 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
t x l tx txl |
|---|---|
| matchkey_str |
lethuyxwolfjeffreylperaltacarmenawebbera:2017----:inyrnpattofrinyalrdeoutpe |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
52.56 |
| publishDate |
2017 |
| allfields |
10.1053/j.ajkd.2016.12.023 doi GBVA2017007000025.pica (DE-627)ELV030399017 (ELSEVIER)S0272-6386(17)30511-5 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Le, Thuy X. verfasserin aut Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Elsevier Wolf, Jeffrey L. oth Peralta, Carmen A. oth Webber, Allison B. oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:69 year:2017 number:6 pages:858-862 extent:5 https://doi.org/10.1053/j.ajkd.2016.12.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 69 2017 6 858-862 5 045F 610 |
| spelling |
10.1053/j.ajkd.2016.12.023 doi GBVA2017007000025.pica (DE-627)ELV030399017 (ELSEVIER)S0272-6386(17)30511-5 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Le, Thuy X. verfasserin aut Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Elsevier Wolf, Jeffrey L. oth Peralta, Carmen A. oth Webber, Allison B. oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:69 year:2017 number:6 pages:858-862 extent:5 https://doi.org/10.1053/j.ajkd.2016.12.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 69 2017 6 858-862 5 045F 610 |
| allfields_unstemmed |
10.1053/j.ajkd.2016.12.023 doi GBVA2017007000025.pica (DE-627)ELV030399017 (ELSEVIER)S0272-6386(17)30511-5 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Le, Thuy X. verfasserin aut Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Elsevier Wolf, Jeffrey L. oth Peralta, Carmen A. oth Webber, Allison B. oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:69 year:2017 number:6 pages:858-862 extent:5 https://doi.org/10.1053/j.ajkd.2016.12.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 69 2017 6 858-862 5 045F 610 |
| allfieldsGer |
10.1053/j.ajkd.2016.12.023 doi GBVA2017007000025.pica (DE-627)ELV030399017 (ELSEVIER)S0272-6386(17)30511-5 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Le, Thuy X. verfasserin aut Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Elsevier Wolf, Jeffrey L. oth Peralta, Carmen A. oth Webber, Allison B. oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:69 year:2017 number:6 pages:858-862 extent:5 https://doi.org/10.1053/j.ajkd.2016.12.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 69 2017 6 858-862 5 045F 610 |
| allfieldsSound |
10.1053/j.ajkd.2016.12.023 doi GBVA2017007000025.pica (DE-627)ELV030399017 (ELSEVIER)S0272-6386(17)30511-5 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Le, Thuy X. verfasserin aut Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Elsevier Wolf, Jeffrey L. oth Peralta, Carmen A. oth Webber, Allison B. oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:69 year:2017 number:6 pages:858-862 extent:5 https://doi.org/10.1053/j.ajkd.2016.12.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 69 2017 6 858-862 5 045F 610 |
| language |
English |
| source |
Enthalten in The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested Philadelphia, Pa volume:69 year:2017 number:6 pages:858-862 extent:5 |
| sourceStr |
Enthalten in The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested Philadelphia, Pa volume:69 year:2017 number:6 pages:858-862 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Regenerative Energieformen alternative Energieformen |
| institution |
findex.gbv.de |
| topic_facet |
multiple myeloma kidney failure case report renal replacement therapy (RRT) outcomes end-stage renal disease (ESRD) remission light chain deposition disease (LCDD) autologous stem cell transplantation (ASCT) RRT modality bortezomib hematologic malignancy Kidney transplantation |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| authorswithroles_txt_mv |
Le, Thuy X. @@aut@@ Wolf, Jeffrey L. @@oth@@ Peralta, Carmen A. @@oth@@ Webber, Allison B. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011405082 |
| dewey-sort |
3610 |
| id |
ELV030399017 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030399017</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625181531.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.ajkd.2016.12.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017007000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030399017</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0272-6386(17)30511-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">52.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Le, Thuy X.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">multiple myeloma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">kidney failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">case report</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal replacement therapy (RRT)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">end-stage renal disease (ESRD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">remission</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">light chain deposition disease (LCDD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">autologous stem cell transplantation (ASCT)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RRT modality</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">bortezomib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hematologic malignancy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kidney transplantation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wolf, Jeffrey L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peralta, Carmen A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Webber, Allison B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Saunders</subfield><subfield code="t">The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested</subfield><subfield code="d">2013</subfield><subfield code="d">AJKD : official journal of the National Kidney Foundation</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV011405082</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:858-862</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.ajkd.2016.12.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">52.56</subfield><subfield code="j">Regenerative Energieformen</subfield><subfield code="j">alternative Energieformen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">2017</subfield><subfield code="e">6</subfield><subfield code="h">858-862</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Le, Thuy X. |
| spellingShingle |
Le, Thuy X. ddc 610 ddc 530 bkl 52.56 Elsevier multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports |
| authorStr |
Le, Thuy X. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011405082 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 530 - Physics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DNB 610 VZ 530 VZ 52.56 bkl Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation Elsevier |
| topic |
ddc 610 ddc 530 bkl 52.56 Elsevier multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation |
| topic_unstemmed |
ddc 610 ddc 530 bkl 52.56 Elsevier multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation |
| topic_browse |
ddc 610 ddc 530 bkl 52.56 Elsevier multiple myeloma Elsevier kidney failure Elsevier case report Elsevier renal replacement therapy (RRT) Elsevier outcomes Elsevier end-stage renal disease (ESRD) Elsevier remission Elsevier light chain deposition disease (LCDD) Elsevier autologous stem cell transplantation (ASCT) Elsevier RRT modality Elsevier bortezomib Elsevier hematologic malignancy Elsevier Kidney transplantation |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j l w jl jlw c a p ca cap a b w ab abw |
| hierarchy_parent_title |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| hierarchy_parent_id |
ELV011405082 |
| dewey-tens |
610 - Medicine & health 530 - Physics |
| hierarchy_top_title |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011405082 |
| title |
Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports |
| ctrlnum |
(DE-627)ELV030399017 (ELSEVIER)S0272-6386(17)30511-5 |
| title_full |
Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports |
| author_sort |
Le, Thuy X. |
| journal |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| journalStr |
The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
858 |
| author_browse |
Le, Thuy X. |
| container_volume |
69 |
| physical |
5 |
| class |
610 610 DNB 610 VZ 530 VZ 52.56 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Le, Thuy X. |
| doi_str_mv |
10.1053/j.ajkd.2016.12.023 |
| dewey-full |
610 530 |
| title_sort |
kidney transplantation for kidney failure due to multiple myeloma: case reports |
| title_auth |
Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports |
| abstract |
Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. |
| abstractGer |
Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. |
| abstract_unstemmed |
Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 |
| container_issue |
6 |
| title_short |
Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports |
| url |
https://doi.org/10.1053/j.ajkd.2016.12.023 |
| remote_bool |
true |
| author2 |
Wolf, Jeffrey L. Peralta, Carmen A. Webber, Allison B. |
| author2Str |
Wolf, Jeffrey L. Peralta, Carmen A. Webber, Allison B. |
| ppnlink |
ELV011405082 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1053/j.ajkd.2016.12.023 |
| up_date |
2024-07-06T17:28:20.802Z |
| _version_ |
1803851557296406528 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030399017</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625181531.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.ajkd.2016.12.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017007000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030399017</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0272-6386(17)30511-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">52.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Le, Thuy X.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transplantation centers have historically considered a history of multiple myeloma as a contraindication to kidney transplantation due to high recurrence rates and poor transplant survival. However, there have been significant advances in the treatment of multiple myeloma, with improved patient survival, which may allow for successful kidney transplantation in these patients. We report on 4 patients who underwent kidney transplantation at our institution between 2009 and 2015 after having achieved a very good partial response or better with chemotherapy and autologous stem cell transplantation. All 4 patients received kidneys from living donors; 2 underwent induction therapy with basiliximab, and 2, with thymoglobulin. One patient had progression of myeloma, which responded well to therapy. All had functioning transplants at 1 year after kidney transplantation. No patients experienced a rejection episode or infections with BK polyomavirus or cytomegalovirus, with follow-up ranging from 16 to 58 months after kidney transplantation. Our experience suggests that kidney transplantation is feasible in a subset of patients with multiple myeloma. Future studies are necessary to compare outcomes in these patients with other high-risk patients undergoing kidney transplantation.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">multiple myeloma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">kidney failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">case report</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal replacement therapy (RRT)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">end-stage renal disease (ESRD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">remission</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">light chain deposition disease (LCDD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">autologous stem cell transplantation (ASCT)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RRT modality</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">bortezomib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hematologic malignancy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kidney transplantation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wolf, Jeffrey L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peralta, Carmen A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Webber, Allison B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Saunders</subfield><subfield code="t">The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested</subfield><subfield code="d">2013</subfield><subfield code="d">AJKD : official journal of the National Kidney Foundation</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV011405082</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:858-862</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.ajkd.2016.12.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">52.56</subfield><subfield code="j">Regenerative Energieformen</subfield><subfield code="j">alternative Energieformen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">2017</subfield><subfield code="e">6</subfield><subfield code="h">858-862</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399643 |